49,291 Shares in LivaNova PLC $LIVN Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

Key Points

• Virginia Retirement Systems acquired 49,291 shares of LivaNova, valued at approximately $4.05 million, giving it a 0.09% stake. Institutional investors and hedge funds collectively own 97.64% of the company.
• LivaNova exceeded quarterly expectations, reporting $1.26 in EPS versus the $1.09 consensus estimate and revenue of $390.59 million, up 10.8% year over year.
• Analysts maintain a generally positive outlook, with six Buy and five Hold ratings and a “Moderate Buy” consensus. Recent price-target increases include Needham’s $93 target and Piper Sandler’s $90 target, while two directors sold shares.

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in LivaNova PLC (NASDAQ:LIVN - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 49,291 shares of the company's stock, valued at approximately $4,053,000. VIRGINIA RETIREMENT SYSTEMS ET Al owned 0.09% of LivaNova at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of LIVN. UMB Bank n.a. boosted its stake in shares of LivaNova by 22.6% in the 4th quarter. UMB Bank n.a. now owns 971 shares of the company's stock valued at $60,000 after purchasing an additional 179 shares in the last quarter. State of Michigan Retirement System increased its position in shares of LivaNova by 1.5% during the 1st quarter. State of Michigan Retirement System now owns 13,111 shares of the company's stock worth $833,000 after purchasing an additional 200 shares in the last quarter. Hantz Financial Services Inc. lifted its holdings in LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company's stock valued at $27,000 after purchasing an additional 267 shares during the last quarter. GAMMA Investing LLC lifted its holdings in LivaNova by 18.2% during the 2nd quarter. GAMMA Investing LLC now owns 1,838 shares of the company's stock valued at $151,000 after purchasing an additional 283 shares during the last quarter. Finally, Parallel Advisors LLC boosted its position in LivaNova by 28.8% in the fourth quarter. Parallel Advisors LLC now owns 1,266 shares of the company's stock valued at $78,000 after buying an additional 283 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Stock Down 2.2%

Shares of LIVN opened at $78.93 on Thursday. The business's fifty day moving average price is $80.56 and its two-hundred day moving average price is $73.22. The firm has a market capitalization of $4.35 billion, a price-to-earnings ratio of 23.35 and a beta of 0.87. LivaNova PLC has a 52 week low of $48.82 and a 52 week high of $85.76. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.45.

LivaNova (NASDAQ:LIVN - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.17. The business had revenue of $390.59 million for the quarter, compared to analyst estimates of $380.50 million. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The firm's revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.05 earnings per share. On average, analysts predict that LivaNova PLC will post 3.77 earnings per share for the current year.

Insider Transactions at LivaNova

In other news, Director Brooke Story sold 2,300 shares of LivaNova stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $81.42, for a total transaction of $187,266.00. Following the completion of the sale, the director owned 7,488 shares in the company, valued at $609,672.96. The trade was a 23.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Francesco Bianchi sold 1,650 shares of the business's stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $79.72, for a total transaction of $131,538.00. Following the sale, the director directly owned 7,934 shares of the company's stock, valued at approximately $632,498.48. This trade represents a 17.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.35% of the company's stock.

Analysts Set New Price Targets

LIVN has been the subject of several recent analyst reports. Freedom Capital raised shares of LivaNova to a "hold" rating in a report on Tuesday, June 30th. Weiss Ratings upgraded LivaNova from a "hold (c)" rating to a "hold (c+)" rating in a research report on Tuesday, August 18th. Needham & Company LLC increased their price target on LivaNova from $81.00 to $93.00 and gave the stock a "buy" rating in a research report on Wednesday, August 5th. KeyCorp raised their price target on LivaNova from $83.00 to $92.00 and gave the company an "overweight" rating in a report on Monday, June 22nd. Finally, Piper Sandler reiterated an "overweight" rating and issued a $90.00 price objective (up from $87.00) on shares of LivaNova in a research report on Wednesday, September 2nd. Six research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $84.12.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company's primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.

Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.